A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Rasagiline (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms R2
- 03 Apr 2018 Planned primary completion date changed from 15 Feb 2018 to 15 Feb 2019.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2017 Planned End Date changed from 1 May 2017 to 15 Feb 2019.